TCR

Dec 29, 2023

HPK1 Inhibitors: A Promising Frontier in Immuno-Oncology Therapeutics

Jan 12, 2018

Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal

Newsletter/Whitepaper